Market Overview

Primary Immune Deficiency (PID) - 2018 Pipeline Insights featuring Shire, GlaxoSmithKline, Novartis and others - ResearchAndMarkets.com

Share:

The "Primary
Immune Deficiency (PID) - Pipeline Insight, 2018"
drug
pipelines has been added to ResearchAndMarkets.com's
offering.

This report offers comprehensive Insight of the pipeline (under
development) therapeutics scenario and growth prospects across Primary
Immune Deficiency (PID) development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental
Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

The report assesses the active Primary Immune Deficiency (PID) pipeline
products by developmental stage, product type, molecule type, and
administration route.

Scope

  • The report provides a snapshot of the pipeline development for the
    Primary Immune Deficiency (PID)
  • The report covers pipeline activity across the complete product
    development cycle i.e. clinical, pre-clinical and discovery stages for
    the Primary Immune Deficiency (PID)
  • The report provides pipeline product profiles which includes product
    description, developmental activities, licensors & collaborators and
    chemical information
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development, route of administration, and molecule
    type for Primary Immune Deficiency (PID)
  • The report also covers the dormant and discontinued pipeline projects
    related to the Primary Immune Deficiency (PID)

Companies Featured

  • ADMA Biologics Inc
  • Biotest AG
  • Genethon SA
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Novartis AG
  • ProMetic Life Sciences Inc
  • Shire Plc
  • Taiga Biotechnologies Inc
  • UCB SA

Key Topics Covered

1. Report Introduction

2. Primary Immune Deficiency (PID) Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wq3r54/primary_immune?w=4

View Comments and Join the Discussion!